Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab combined with cetuximab for advanced head and neck squamous cell carcinoma
CTR20210364Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2021; status: completed.
02
Drugs
toripalimabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20210364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210364.